TY - JOUR
T1 - Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
AU - Eteleeb, Abdallah M.
AU - Novotny, Brenna C.
AU - Tarraga, Carolina Soriano
AU - Sohn, Christopher
AU - Dhungel, Eliza
AU - Brase, Logan
AU - Nallapu, Aasritha
AU - Buss, Jared
AU - Farias, Fabiana
AU - Bergmann, Kristy
AU - Bradley, Joseph
AU - Norton, Joanne
AU - Gentsch, Jen
AU - Wang, Fengxian
AU - Davis, Albert A.
AU - Morris, John C.
AU - Karch, Celeste M.
AU - Perrin, Richard J.
AU - Benitez, Bruno A.
AU - Harari, Oscar
N1 - Publisher Copyright:
© 2024 Eteleeb et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2024/4
Y1 - 2024/4
N2 - Unbiased data-driven omic approaches are revealing the molecular : heterogeneity of Alzheimer disease. Here, we used machine learning approaches to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles with clinical and neuropathological data from multiple human AD cohorts. We discovered 4 unique multimodal molecular profiles, one of them showing signs of poor cognitive function, a faster pace of disease progression, shorter survival with the disease, severe neurodegeneration and astrogliosis, and reduced levels of metabolomic profiles. We found this molecular profile to be present in multiple affected cortical regions associated with higher Braak tau scores and significant dysregulation of synapse-related genes, endocytosis, phagosome, and mTOR signaling pathways altered in AD early and late stages. AD cross-omics data integration with transcriptomic data from an SNCA mouse model revealed an overlapping signature. Furthermore, we leveraged single-nuclei RNA-seq data to identify distinct cell-types that most likely mediate molecular profiles. Lastly, we identified that the multimodal clusters uncovered cerebrospinal fluid biomarkers poised to monitor AD progression and possibly cognition. Our cross-omics analyses provide novel critical molecular insights into AD.
AB - Unbiased data-driven omic approaches are revealing the molecular : heterogeneity of Alzheimer disease. Here, we used machine learning approaches to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles with clinical and neuropathological data from multiple human AD cohorts. We discovered 4 unique multimodal molecular profiles, one of them showing signs of poor cognitive function, a faster pace of disease progression, shorter survival with the disease, severe neurodegeneration and astrogliosis, and reduced levels of metabolomic profiles. We found this molecular profile to be present in multiple affected cortical regions associated with higher Braak tau scores and significant dysregulation of synapse-related genes, endocytosis, phagosome, and mTOR signaling pathways altered in AD early and late stages. AD cross-omics data integration with transcriptomic data from an SNCA mouse model revealed an overlapping signature. Furthermore, we leveraged single-nuclei RNA-seq data to identify distinct cell-types that most likely mediate molecular profiles. Lastly, we identified that the multimodal clusters uncovered cerebrospinal fluid biomarkers poised to monitor AD progression and possibly cognition. Our cross-omics analyses provide novel critical molecular insights into AD.
UR - http://www.scopus.com/inward/record.url?scp=85191966073&partnerID=8YFLogxK
U2 - 10.1371/journal.pbio.3002607
DO - 10.1371/journal.pbio.3002607
M3 - Article
C2 - 38687811
AN - SCOPUS:85191966073
SN - 1544-9173
VL - 22
JO - PLoS biology
JF - PLoS biology
IS - 4 April
M1 - e3002607
ER -